Vanda Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Vanda PharmaceuticalsDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -65.6% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind rückläufig mit einer durchschnittlichen Rate von 3.9% pro Jahr.

Wichtige Informationen

-65.6%

Wachstumsrate der Gewinne

-66.5%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	-3.9%
Eigenkapitalrendite	-3.0%
Netto-Marge	-8.6%
Letzte Ertragsaktualisierung	30 Sep 2024

Jüngste Aktualisierungen vergangener Leistungen

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Feb 15

Recent updates

Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids

Sep 05

Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over

Aug 08

Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest

Jun 18

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

Apr 05

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Feb 15

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Feb 13

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Feb 10

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Nov 11

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

May 12

Aufschlüsselung der Einnahmen und Ausgaben

Wie Vanda Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGM:VNDA Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Sep 24	191	-16	131	79
30 Jun 24	182	-11	118	79
31 Mar 24	178	-5	107	79
31 Dec 23	193	3	113	77
30 Sep 23	212	12	122	71
30 Jun 23	238	15	127	79
31 Mar 23	257	16	132	84
31 Dec 22	254	6	136	86
30 Sep 22	258	6	137	87
30 Jun 22	263	11	140	81
31 Mar 22	266	18	135	80
31 Dec 21	269	33	124	75
30 Sep 21	268	34	126	71
30 Jun 21	259	32	128	64
31 Mar 21	253	32	133	56
31 Dec 20	248	23	141	56
30 Sep 20	241	19	142	54
30 Jun 20	241	114	138	53
31 Mar 20	237	117	136	51
31 Dec 19	227	116	130	49
30 Sep 19	219	122	118	48
30 Jun 19	209	28	113	49
31 Mar 19	197	22	110	47
31 Dec 18	193	25	106	44
30 Sep 18	184	13	112	41
30 Jun 18	177	1	117	40
31 Mar 18	171	-5	120	37
31 Dec 17	165	-16	124	39
30 Sep 17	159	-14	117	36
30 Jun 17	156	-10	107	33
31 Mar 17	150	-13	101	32
31 Dec 16	146	-18	100	29
30 Sep 16	140	-32	105	30
30 Jun 16	129	-41	101	33
31 Mar 16	121	-42	95	32
31 Dec 15	110	-40	85	29
30 Sep 15	93	45	73	25
30 Jun 15	80	53	66	19
31 Mar 15	63	36	76	16
31 Dec 14	50	20	85	19
30 Sep 14	44	-57	77	21
30 Jun 14	37	-61	72	25
31 Mar 14	35	-43	49	28
31 Dec 13	34	-21	25	29

Qualität der Erträge: VNDA ist derzeit unrentabel.

Wachsende Gewinnspanne: VNDA ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: VNDA ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 65.6% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von VNDA verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: VNDA ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (16.6%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: VNDA hat eine negative Eigenkapitalrendite (-3.03%), da es derzeit unrentabel ist.

Vanda Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Vanda Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 06, 2024

Vanda Pharmaceuticals Inc. to Report Q2, 2024 Results on Jul 31, 2024

First quarter 2024 earnings released: US$0.072 loss per share (vs US$0.057 profit in 1Q 2023)

Vanda Pharmaceuticals Inc. to Report Q1, 2024 Results on May 08, 2024

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Vanda Pharmaceuticals Inc. Revises Revenue Guidance for the Full Year 2024

Vanda Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 06, 2024

Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA for approximately $490 million.

FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis

Vanda's Struggles Persist Despite New Drug Launches And Takeover Bids

Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over

Vanda Pharmaceuticals Inc. Reinstates Financial Guidance for the Full Year 2024

Vanda Pharmaceuticals Inc. to Report Q2, 2024 Results on Jul 31, 2024

Vanda Pharmaceuticals Inc.(NasdaqGM:VNDA) dropped from Russell 2000 Value-Defensive Index

Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc. (NYSE:BLK), Butler Hall Capital LLC, Shareholder Capital LLC and others.

Cycle Pharmaceuticals Limited cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA).

Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest

Cycle Pharmaceuticals Limited made a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) for approximately $490 million.

Future Pak, Ltd. cancelled the acquisition of Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., Renaissance Technologies LLC, BlackRock, Inc. (NYSE:BLK), Butler Hall Capital LLC, Shareholder Capital LLC and others.

Vanda Pharmaceuticals Inc. Reports Positive Results from A Second Phase III Study of Tradipitant in Motion Sickness

First quarter 2024 earnings released: US$0.072 loss per share (vs US$0.057 profit in 1Q 2023)

Price target increased by 23% to US$5.21

Vanda Pharmaceuticals Inc. to Report Q1, 2024 Results on May 08, 2024

Future Pak, Ltd. submits a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others for approximately $450 million.

Future Pak, Ltd. submits a proposal to acquire Vanda Pharmaceuticals Inc. (NasdaqGM:VNDA) from The Vanguard Group, Inc., State Street Corporation (NYSE:STT), BlackRock, Inc. (NYSE:BLK), Dimensional Fund Advisors LP and others for approximately $450 million.

Consensus EPS estimates fall from profit to US$0.06 loss, revenue upgraded

Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much

New minor risk - Share price stability

Vanda Pharmaceuticals' Fanapt (Iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder

Insider recently sold US$73k worth of stock

Founder notifies of intention to sell stock

Vanda Pharmaceuticals Announces FDA Update for Supplemental NDA for HETLIOZ in the Treatment of Insomnia

Vanda Pharmaceuticals' (NASDAQ:VNDA) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Consensus revenue estimates increase by 27%

Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash

Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Low P/S No Reason For Excitement

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia

Vanda Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 07, 2024

Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Approval for VTR-297 for the Treatment of Onychomycosis

Vanda Pharmaceuticals Inc. Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

Now 21% undervalued after recent price drop

Vanda Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis

Now 21% undervalued after recent price drop

News Flash: One Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Analyst Has Been Trimming Their Revenue Forecasts

Third quarter 2023 earnings released: EPS: US$0.002 (vs US$0.058 in 3Q 2022)

Vanda Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 08, 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vanda Pharmaceuticals Inc. to Report Q2, 2023 Results on Jul 27, 2023

Senior VP recently sold US$96k worth of stock

Senior VP notifies of intention to sell stock

Vanda Pharmaceuticals Inc Reports Results from a Phase III study of Tradipitant in Motion Sickness

One Forecaster Is Now More Bearish On Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Than They Used To Be

Vanda Pharmaceuticals Inc. Responds to the Ruling in its Hetlioz(R) Abbreviated New Drug Application Appeal

First quarter 2023 earnings released: EPS: US$0.057 (vs US$0.12 loss in 1Q 2022)

Aufschlüsselung der Einnahmen und Ausgaben

Gewinn- und Umsatzhistorie

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Eigenkapitalrendite

Kapitalrendite

Rendite auf das eingesetzte Kapital

Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren